T1	CHEM 54 64	durvalumab
#1	AnnotatorNotes T1	C4055109; durvalumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T2	PROC 96 107	tratamiento
#2	AnnotatorNotes T2	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T3	DISO 125 156	cáncer de pulmón no microcítico
#3	AnnotatorNotes T3	C0007131; Non-Small Cell Lung Carcinoma; Neoplastic Process
T4	PROC 188 271	Ensayo fase III, doble ciego, controlado con placebo, Internacional y multicéntrico
T5	PROC 275 309	tratamiento neoadyuvante/adyuvante
T6	CHEM 313 323	Durvalumab
#4	AnnotatorNotes T6	C4055109; durvalumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T7	PROC 332 343	tratamiento
#5	AnnotatorNotes T7	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T8	DISO 361 392	cáncer de pulmón no microcítico
#6	AnnotatorNotes T8	C0007131; Non-Small Cell Lung Carcinoma; Neoplastic Process
T9	DISO 469 500	cáncer de pulmón no microcítico
#7	AnnotatorNotes T9	C0007131; Non-Small Cell Lung Carcinoma; Neoplastic Process
T10	DISO 502 506	CPNM
#8	AnnotatorNotes T10	C0007131; Non-Small Cell Lung Carcinoma; Neoplastic Process
T11	DISO 598 629	cáncer de pulmón no microcítico
#9	AnnotatorNotes T11	C0007131; Non-Small Cell Lung Carcinoma; Neoplastic Process
T12	DISO 631 635	CPNM
#10	AnnotatorNotes T12	C0007131; Non-Small Cell Lung Carcinoma; Neoplastic Process
T13	ANAT 676 684	escamoso
#11	AnnotatorNotes T13	C0221909; Squamous epithelium; Tissue
T14	ANAT 690 698	escamoso
#12	AnnotatorNotes T14	C0221909; Squamous epithelium; Tissue
T15	DISO 747 751	CPNM
#13	AnnotatorNotes T15	C0007131; Non-Small Cell Lung Carcinoma; Neoplastic Process
T16	DISO 970 976	lesión
#14	AnnotatorNotes T16	C0221198; Lesion; Finding
T17	DISO 1024 1030	Lesión
#15	AnnotatorNotes T17	C0221198; Lesion; Finding
T18	PROC 1113 1135	terapia inmuno-mediada
T19	PROC 993 1002	irradiada
#16	AnnotatorNotes T19	C1522449; Therapeutic radiology procedure; Therapeutic or Preventive Procedure
T20	CHEM 1168 1191	anticuerpos anti CTLA-4
T21	CHEM 1204 1214	anti-PD-L1
T22	CHEM 1193 1202	anti-PD-1
T23	CHEM 1218 1228	anti-PD-L2
T24	PROC 1241 1249	terapias
#17	AnnotatorNotes T24	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure [Positive entity (double negation context)]
T25	ANAT 1302 1309	órganos
#18	AnnotatorNotes T25	C0178784; Organ; Body Part, Organ, or Organ Component | C1280836; Entire body organ; Body Part, Organ, or Organ Component
T26	ANAT 1312 1318	médula
#19	AnnotatorNotes T26	C0376152; Marrow; Body Part, Organ, or Organ Component | C1550278; Medullary - body parts; Body Part, Organ, or Organ Component
T27	DISO 1381 1389	mutación
T28	PROC 1458 1489	trasplante alogénico de órganos
T29	ANAT 1482 1489	órganos
#20	AnnotatorNotes T29	C0178784; Organ; Body Part, Organ, or Organ Component | C1280836; Entire body organ; Body Part, Organ, or Organ Component
T30	DISO 1494 1532	Trastornos autoinmunes o inflamatorios
T31	DISO 1580 1614	enfermedad inflamatoria intestinal
#21	AnnotatorNotes T31	C0021390; Inflammatory Bowel Diseases; Disease or Syndrome
T32	DISO 1616 1630	diverticulitis
#22	AnnotatorNotes T32	C0012813; Diverticulitis; Disease or Syndrome | C0349774; Diverticulitis of gastrointestinal tract; Disease or Syndrome
T33	DISO 1632 1659	lupus eritematoso sistémico
#23	AnnotatorNotes T33	C0024141; Lupus Erythematosus, Systemic; Disease or Syndrome
T34	DISO 1661 1684	síndrome de sarcoidosis
T35	DISO 1687 1706	síndrome de Wegener
#24	AnnotatorNotes T35	C3495801; Granulomatosis with polyangiitis; Disease or Syndrome
T36	DISO 1732 1747	cáncer primario
#25	AnnotatorNotes T36	C0677930; Primary Neoplasm; Neoplastic Process
T37	DISO 1767 1784	inmunodeficiencia
#26	AnnotatorNotes T37	C0021051; Immunologic Deficiency Syndromes; Disease or Syndrome
T38	DISO 1804 1813	Infección
#27	AnnotatorNotes T38	C0009450; Communicable Diseases; Disease or Syndrome | C3714514; Infection; Pathologic Function
T39	DISO 1832 1844	tuberculosis
#28	AnnotatorNotes T39	C0041296; Tuberculosis; Disease or Syndrome
T40	DISO 1846 1857	hepatitis B
#29	AnnotatorNotes T40	C0019163; Hepatitis B; Disease or Syndrome
T41	DISO 1909 1913	CPNM
#30	AnnotatorNotes T41	C0007131; Non-Small Cell Lung Carcinoma; Neoplastic Process
T42	PROC 1930 1959	evaluación multidisciplinaria
T43	PROC 1985 2027	tratamiento preoperatorio con radioterapia
T44	DISO 2079 2100	metástasis cerebrales
#31	AnnotatorNotes T44	C0220650; Metastatic malignant neoplasm to brain; Neoplastic Process | C0555278; Cerebral metastasis; Neoplastic Process
T45	DISO 2103 2134	compresión de la médula espinal
#32	AnnotatorNotes T45	C0037926; Compression of spinal cord; Disease or Syndrome
T46	DISO 2138 2142	CPNM
#33	AnnotatorNotes T46	C0007131; Non-Small Cell Lung Carcinoma; Neoplastic Process
T47	ANAT 2212 2228	células pequeñas
T48	DISO 2231 2235	CPNM
#34	AnnotatorNotes T48	C0007131; Non-Small Cell Lung Carcinoma; Neoplastic Process
T49	PROC 2289 2304	segmentectomías
#35	AnnotatorNotes T49	C2987624; Segmentectomy; Therapeutic or Preventive Procedure
T50	PROC 2307 2326	resecciones en cuña
#36	AnnotatorNotes T50	C0184909; wedge resections; Therapeutic or Preventive Procedure
T51	ANAT 135 141	pulmón
#37	AnnotatorNotes T51	C0024109; Lung; Body Part, Organ, or Organ Component | C1278908; Entire lung; Body Part, Organ, or Organ Component
T52	ANAT 145 156	microcítico
#38	AnnotatorNotes T52	C1514085; Neoplastic Small Cell; Cell | C1518241; Malignant Small Cell; Cell
T53	ANAT 371 377	pulmón
#39	AnnotatorNotes T53	C0024109; Lung; Body Part, Organ, or Organ Component | C1278908; Entire lung; Body Part, Organ, or Organ Component
T54	ANAT 381 392	microcítico
#40	AnnotatorNotes T54	C1514085; Neoplastic Small Cell; Cell | C1518241; Malignant Small Cell; Cell
T55	ANAT 479 485	pulmón
#41	AnnotatorNotes T55	C0024109; Lung; Body Part, Organ, or Organ Component | C1278908; Entire lung; Body Part, Organ, or Organ Component
T56	ANAT 489 500	microcítico
#42	AnnotatorNotes T56	C1514085; Neoplastic Small Cell; Cell | C1518241; Malignant Small Cell; Cell
T57	ANAT 608 614	pulmón
#43	AnnotatorNotes T57	C0024109; Lung; Body Part, Organ, or Organ Component | C1278908; Entire lung; Body Part, Organ, or Organ Component
T58	ANAT 618 629	microcítico
#44	AnnotatorNotes T58	C1514085; Neoplastic Small Cell; Cell | C1518241; Malignant Small Cell; Cell
T59	CHEM 1254 1278	vacunas anticancerígenas
#45	AnnotatorNotes T59	C0376659; Cancer Vaccines; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance [Positive entity (double negation context)]
T60	ANAT 1604 1614	intestinal
#46	AnnotatorNotes T60	C0021853; Intestines; Body Part, Organ, or Organ Component | C1318303; Entire intestine; Body Part, Organ, or Organ Component
T61	DISO 1860 1893	virus de inmunodeficiencia humana
#47	AnnotatorNotes T61	C0458074; Human immunodeficiency virus (HIV) status; Finding
T62	ANAT 2090 2100	cerebrales
#48	AnnotatorNotes T62	C0242202; Cerebrum; Body Part, Organ, or Organ Component | C1269537; Entire brain; Body Part, Organ, or Organ Component | C1280654; Entire cerebrum; Body Part, Organ, or Organ Component
T63	ANAT 2120 2134	médula espinal
#49	AnnotatorNotes T63	C0037925; Spinal Cord; Body Part, Organ, or Organ Component | C1278836; Entire spinal cord; Body Part, Organ, or Organ Component
T64	Date 12 16	2018
T65	LIVB 111 120	pacientes
#50	AnnotatorNotes T65	C0030705; Patients; Patient or Disabled Group
T66	Neg_cue 142 144	no
T67	LIVB 347 356	pacientes
#51	AnnotatorNotes T67	C0030705; Patients; Patient or Disabled Group
T68	Neg_cue 378 380	no
T69	LIVB 455 464	Pacientes
#52	AnnotatorNotes T69	C0030705; Patients; Patient or Disabled Group
T70	Neg_cue 486 488	no
T71	LIVB 584 593	Pacientes
#53	AnnotatorNotes T71	C0030705; Patients; Patient or Disabled Group
T72	Neg_cue 615 617	no
T73	Neg_cue 687 689	no
T74	Age 734 743	≥ 18 años
T75	Neg_cue 978 980	no
T76	Neg_cue 1089 1092	Sin
T78	LIVB 1356 1364	paciente
#54	AnnotatorNotes T78	C0030705; Patients; Patient or Disabled Group
T80	LIVB 1963 1972	Pacientes
#55	AnnotatorNotes T80	C0030705; Patients; Patient or Disabled Group
T81	Date 1997 2010	preoperatorio
#56	AnnotatorNotes T81	C0445204; Preoperative; Temporal Concept | C2712277; Preoperative Period; Temporal Concept
T82	LIVB 2065 2074	Pacientes
#57	AnnotatorNotes T82	C0030705; Patients; Patient or Disabled Group
T83	LIVB 2241 2250	Pacientes
#58	AnnotatorNotes T83	C0030705; Patients; Patient or Disabled Group
T77	PHYS 1282 1289;1299 1309	Función de órganos
#59	AnnotatorNotes T77	C1254358; Organ or Tissue Function; Organ or Tissue Function
T84	PROC 1346 1351	PD-L1
#60	AnnotatorNotes T84	C4722206; Programmed Death Ligand 1 Measurement; Laboratory Procedure
T85	GENE 1390 1394	EGFR
#61	AnnotatorNotes T85	C1414313; EGFR gene; Gene or Genome
T86	GENE 1397 1400	ALK
#62	AnnotatorNotes T86	C1332080; ALK gene; Gene or Genome
T87	PHYS 1282 1289;1299 1301;1312 1318	Función de médula
#63	AnnotatorNotes T87	C1254358; Organ or Tissue Function; Organ or Tissue Function
T79	PROC 2192 2202	Histología
#64	AnnotatorNotes T79	C0344441; Histology Procedure; Laboratory Procedure
T88	PROC 815 844	histológica o citológicamente
#65	AnnotatorNotes T88	C1305671; Cytology procedure; Laboratory Procedure + C0344441; Histology Procedure; Laboratory Procedure
A1	Assertion T52 Negated
A2	Assertion T54 Negated
A3	Assertion T56 Negated
A4	Assertion T58 Negated
A5	Assertion T14 Negated
A6	Assertion T19 Negated
A7	Assertion T18 Negated
A8	Assertion T20 Negated
A9	Assertion T22 Negated
A10	Assertion T21 Negated
A11	Assertion T23 Negated
A12	Status T19 History_of
A13	Status T18 History_of
A14	Status T20 History_of
A15	Status T22 History_of
A16	Status T21 History_of
A17	Status T23 History_of
A18	Status T28 History_of
A19	Status T36 History_of
A20	Status T37 History_of
A21	Status T30 History_of
A22	Status T31 History_of
A23	Status T32 History_of
A24	Status T33 History_of
A25	Status T34 History_of
A26	Status T35 History_of
#66	AnnotatorNotes T5	C0677850; Adjuvant therapy; Therapeutic or Preventive Procedure + C0600558; Neoadjuvant Therapy; Therapeutic or Preventive Procedure
#67	AnnotatorNotes T27	C1705285; Mutation Abnormality; Cell or Molecular Dysfunction
#68	AnnotatorNotes T30	C0004364; Autoimmune Diseases; Disease or Syndrome + C1290884; Inflammatory disorder; Disease or Syndrome
#69	AnnotatorNotes T42	C0729737; Multidisciplinary assessment; Diagnostic Procedure 
#70	AnnotatorNotes T22	C4289971; Anti-PD-L1 Monoclonal Antibody; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
#71	AnnotatorNotes T21	C4289971; Anti-PD-L1 Monoclonal Antibody; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
R1	Negation Arg1:T66 Arg2:T52	
R2	Negation Arg1:T68 Arg2:T54	
R3	Negation Arg1:T70 Arg2:T56	
R4	Negation Arg1:T72 Arg2:T58	
R5	Negation Arg1:T73 Arg2:T14	
R6	Negation Arg1:T75 Arg2:T19	
R7	Negation Arg1:T76 Arg2:T18	
R8	Negation Arg1:T76 Arg2:T20	
R9	Negation Arg1:T76 Arg2:T22	
R10	Negation Arg1:T76 Arg2:T21	
R11	Negation Arg1:T76 Arg2:T23	
T89	Quantifier_or_Qualifier 78 87	adyuvante
#72	AnnotatorNotes T89	C1522673; Adjuvant; Functional Concept
R12	Has_Quantifier_or_Qualifier Arg1:T1 Arg2:T89	
T90	Quantifier_or_Qualifier 65 77	neoadyuvante
R13	Has_Quantifier_or_Qualifier Arg1:T1 Arg2:T90	
R14	Used_for Arg1:T1 Arg2:T2	
R15	Experiences Arg1:T65 Arg2:T1	
R16	Experiences Arg1:T65 Arg2:T3	
R17	Location_of Arg1:T51 Arg2:T3	
R18	Location_of Arg1:T52 Arg2:T3	
T91	Quantifier_or_Qualifier 157 166	resecable
#73	AnnotatorNotes T91	C1514888; Resectable; Qualitative Concept
R19	Has_Quantifier_or_Qualifier Arg1:T3 Arg2:T91	
T92	Quantifier_or_Qualifier 393 402	resecable
#74	AnnotatorNotes T92	C1514888; Resectable; Qualitative Concept
R20	Has_Quantifier_or_Qualifier Arg1:T8 Arg2:T92	
R21	Location_of Arg1:T53 Arg2:T8	
R22	Location_of Arg1:T54 Arg2:T8	
T93	Quantifier_or_Qualifier 406 423	estadios II y III
R23	Has_Quantifier_or_Qualifier Arg1:T8 Arg2:T93	
R24	Experiences Arg1:T67 Arg2:T8	
R25	Experiences Arg1:T67 Arg2:T5	
R26	Experiences Arg1:T67 Arg2:T6	
R27	Used_for Arg1:T6 Arg2:T7	
T94	Quantifier_or_Qualifier 531 557	estadio IIA a estadio IIIB
R28	Location_of Arg1:T55 Arg2:T9	
R29	Location_of Arg1:T56 Arg2:T9	
R30	Location_of Arg1:T55 Arg2:T10	
R31	Location_of Arg1:T56 Arg2:T10	
R32	Experiences Arg1:T69 Arg2:T9	
R33	Experiences Arg1:T69 Arg2:T10	
R34	Has_Quantifier_or_Qualifier Arg1:T9 Arg2:T94	
R35	Has_Quantifier_or_Qualifier Arg1:T10 Arg2:T94	
R36	Experiences Arg1:T71 Arg2:T11	
R37	Location_of Arg1:T57 Arg2:T11	
R38	Location_of Arg1:T58 Arg2:T11	
R39	Location_of Arg1:T57 Arg2:T12	
R40	Location_of Arg1:T58 Arg2:T12	
T95	Quantifier_or_Qualifier 637 646	resecable
#75	AnnotatorNotes T95	C1514888; Resectable; Qualitative Concept
R41	Has_Quantifier_or_Qualifier Arg1:T11 Arg2:T95	
R42	Has_Quantifier_or_Qualifier Arg1:T12 Arg2:T95	
T96	Quantifier_or_Qualifier 752 761	resecable
#76	AnnotatorNotes T96	C1514888; Resectable; Qualitative Concept
R43	Has_Quantifier_or_Qualifier Arg1:T15 Arg2:T96	
T97	Quantifier_or_Qualifier 763 800	Estadio IIA (p.ej. N2) a Estadio IIIB
R44	Has_Quantifier_or_Qualifier Arg1:T15 Arg2:T97	
T98	Observation 1914 1925	irresecable
#77	AnnotatorNotes T98	C4039777; Tumor surgically unresectable; Finding
R45	Has_Quantifier_or_Qualifier Arg1:T41 Arg2:T98	
R48	Location_of Arg1:T13 Arg2:T11	
R49	Location_of Arg1:T13 Arg2:T12	
R50	Location_of Arg1:T14 Arg2:T11	
R51	Location_of Arg1:T14 Arg2:T12	
T99	Quantifier_or_Qualifier 648 674	estadio IIA a estadio IIIB
R52	Has_Quantifier_or_Qualifier Arg1:T11 Arg2:T99	
R53	Has_Quantifier_or_Qualifier Arg1:T12 Arg2:T99	
T100	Observation 782 784	N2
#78	AnnotatorNotes T100	C0441960; N2 category (finding); Finding
R54	Has_Quantifier_or_Qualifier Arg1:T15 Arg2:T100	
T101	CONC 889 923	Eastern Cooperative Oncology Group
#79	AnnotatorNotes T101	C1520224; ECOG performance status; Intellectual Product
T102	CONC 925 929	ECOG
#80	AnnotatorNotes T102	C1520224; ECOG performance status; Intellectual Product
T103	Result_or_Value 934 939	0 o 1
R57	Has_Result_or_Value Arg1:T101 Arg2:T103	
R58	Has_Result_or_Value Arg1:T102 Arg2:T103	
T104	CONC 946 955	inclusión
#81	AnnotatorNotes T104	C1512693; Inclusion; Qualitative Concept
R59	Overlap Arg1:T101 Arg2:T104	
R60	Overlap Arg1:T102 Arg2:T104	
T105	Quantifier_or_Qualifier 959 969	Al menos 1
R61	Has_Quantifier_or_Qualifier Arg1:T16 Arg2:T105	
T106	Quantifier_or_Qualifier 1031 1036	Diana
#82	AnnotatorNotes T106	C1521840; Target; Functional Concept
R62	Has_Quantifier_or_Qualifier Arg1:T17 Arg2:T106	
T107	CONC 1046 1065	criterio RECIST 1.1
#83	AnnotatorNotes T107	C1709926; Response Evaluation Criteria in Solid Tumors; Intellectual Product
R63	Has_Quantifier_or_Qualifier Arg1:T17 Arg2:T105	
T108	CONC 1072 1085	momento basal
#84	AnnotatorNotes T108	C1442488; Baseline; Quantitative Concept
R64	Overlap Arg1:T16 Arg2:T108	
R65	Overlap Arg1:T17 Arg2:T108	
R66	Used_for Arg1:T20 Arg2:T18	
R67	Used_for Arg1:T22 Arg2:T18	
R68	Used_for Arg1:T21 Arg2:T18	
R69	Used_for Arg1:T23 Arg2:T18	
R70	Used_for Arg1:T59 Arg2:T24	
#85	AnnotatorNotes T20	C4289973; Anti-CTLA-4 Monoclonal Antibody; Amino Acid, Peptide, or Protein
R71	Experiences Arg1:T78 Arg2:T84	
T109	Observation 1282 1318	Función adecuada de órganos y médula
R72	Location_of Arg1:T25 Arg2:T77	
R73	Location_of Arg1:T25 Arg2:T109	
R74	Location_of Arg1:T26 Arg2:T87	
R75	Location_of Arg1:T26 Arg2:T109	
T110	Observation 1322 1351	Confirmación del estado PD-L1
#86	AnnotatorNotes T110	C4054275; PD-L1 Overexpression; Finding (?)
R76	Location_of Arg1:T85 Arg2:T27	
R77	Location_of Arg1:T86 Arg2:T27	
R78	Location_of Arg1:T29 Arg2:T28	
T111	Quantifier_or_Qualifier 1533 1540	activos
#87	AnnotatorNotes T111	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R79	Has_Quantifier_or_Qualifier Arg1:T30 Arg2:T111	
T112	Quantifier_or_Qualifier 1794 1800	activa
#88	AnnotatorNotes T112	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
T113	Quantifier_or_Qualifier 1814 1820	activa
#89	AnnotatorNotes T113	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R80	Has_Quantifier_or_Qualifier Arg1:T38 Arg2:T113	
R81	Has_Quantifier_or_Qualifier Arg1:T37 Arg2:T112	
T114	Quantifier_or_Qualifier 1785 1793	primaria
#90	AnnotatorNotes T114	C0205225; Primary; Qualitative Concept
R82	Has_Quantifier_or_Qualifier Arg1:T37 Arg2:T114	
R83	Location_of Arg1:T60 Arg2:T31	
R84	Location_of Arg1:T60 Arg2:T32	
T115	Quantifier_or_Qualifier 1727 1731	otro
#91	AnnotatorNotes T115	C0205394; Other; Qualitative Concept
R85	Has_Quantifier_or_Qualifier Arg1:T36 Arg2:T115	
A27	Status T115 History_of
R86	Overlap Arg1:T43 Arg2:T81	
R87	Experiences Arg1:T80 Arg2:T43	
R88	Location_of Arg1:T62 Arg2:T44	
R89	Location_of Arg1:T63 Arg2:T45	
R90	Experiences Arg1:T82 Arg2:T44	
R91	Experiences Arg1:T82 Arg2:T45	
T116	Quantifier_or_Qualifier 2143 2155	Estadio IIIB
T117	Quantifier_or_Qualifier 2161 2186	Estadios IIIC, IVA, y IVB
R92	Has_Quantifier_or_Qualifier Arg1:T46 Arg2:T116	
R93	Has_Quantifier_or_Qualifier Arg1:T46 Arg2:T117	
T118	Observation 2156 2158	N3
#92	AnnotatorNotes T118	C0441961; N3 category (finding); Finding
R94	Has_Quantifier_or_Qualifier Arg1:T46 Arg2:T118	
#93	AnnotatorNotes T47	C1518241; Malignant Small Cell; Cell (?) | C1514085; Neoplastic Small Cell; Cell (?)
R95	Location_of Arg1:T47 Arg2:T48	
T119	Quantifier_or_Qualifier 2203 2208	mixta
#94	AnnotatorNotes T119	C0205430; Mixed (qualifier value); Functional Concept
R97	Has_Quantifier_or_Qualifier Arg1:T79 Arg2:T119	
R98	Experiences Arg1:T83 Arg2:T49	
R99	Experiences Arg1:T83 Arg2:T50	
T120	Quantifier_or_Qualifier 2282 2286	solo
R100	Has_Quantifier_or_Qualifier Arg1:T49 Arg2:T120	
R101	Has_Quantifier_or_Qualifier Arg1:T50 Arg2:T120	
R102	Experiences Arg1:T71 Arg2:T12	
#95	AnnotatorNotes T28	C0040739; Transplantation, Homologous; Therapeutic or Preventive Procedure
#96	AnnotatorNotes T120	C0205171; Singular; Quantitative Concept
#97	AnnotatorNotes T34	C0036202; Sarcoidosis; Disease or Syndrome (?)
#98	AnnotatorNotes T18	C0021083; Immunotherapy; Therapeutic or Preventive Procedure
#99	AnnotatorNotes T43	C0436204; Preoperative course of radiotherapy; Therapeutic or Preventive Procedure
A28	Experiencer T65 Patient
A29	Experiencer T67 Patient
A30	Experiencer T69 Patient
A31	Experiencer T71 Patient
A32	Experiencer T78 Patient
A33	Experiencer T80 Patient
A34	Experiencer T82 Patient
A35	Experiencer T83 Patient
A36	Status T49 Future
A37	Status T50 Future
